Vaccine
AssigneeGlaxosmithkline Biologicals SA
InventorsElisabeth Marie Monique Bertaud, Ralph Leon Biemans, Nicolas Jean Benoit Moniotte, Laurent Bernard Jean Strodiot
Life of this patent
Estimating the term…
Abstract
The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.
Claims13
An immunogenic composition comprising a sized Streptococcus pneumoniae serotype 6A capsular polysaccharide conjugated to CRM197 carrier protein, wherein the ratio of the carrier protein to the sized serotype 6A capsular polysaccharide is between 1.5:1 and 1:1 (w/w), and wherein the average size (Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 180-400 kDa.
Dependencies are inferred from the claim text.